ADMA Biologics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $119,839 | $107,191 | $81,875 | $73,903 |
Gross Profit | 59,659 | 57,311 | 38,915 | 30,898 |
EBITDA | 42,188 | 41,681 | 23,935 | -9,320 |
EBIT | 40,248 | 39,634 | 21,821 | -11,429 |
Net Income | 35,909 | 32,062 | 17,806 | -17,644 |
Net Change In Cash | 119,839 | 107,191 | 81,875 | 73,903 |
Free Cash Flow | 24,286 | 43,281 | -4,580 | 16,188 |
Cash | 86,707 | 88,244 | 45,325 | 51,352 |
Basic Shares | 244,804 | 242,167 | 236,414 | 225,968 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $258,214 | $154,079 | $80,942 | $42,219 |
Gross Profit | 88,941 | 35,265 | 1,173 | -19,071 |
EBITDA | 5,120 | -39,722 | -53,334 | -59,821 |
EBIT | -3,212 | -46,835 | -58,830 | -63,763 |
Net Income | -28,239 | -85,183 | -84,452 | -87,605 |
Net Change In Cash | 258,214 | 154,079 | 80,942 | 42,219 |
Cost of Revenue | 35,432 | -4,832 | 29,169 | |
Free Cash Flow | 3,819 | -73,419 | -125,880 | -114,729 |
Cash | 51,352 | 86,521 | 51,089 | 55,921 |
Basic Shares | 223,977 | 197,874 | 139,578 | 86,145 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.15 |
2024-06-30 | $0.13 |
2024-03-31 | $0.08 |
2023-12-31 | -$0.08 |
